Clinical trialNCT07719361RecruitingPhase 1Interventional

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

SponsorFlare Therapeutics Inc.Enrollment60Metastatic Castration Resistant Prostate CancerNeoplasms ProstateNeoplasms of ProstateProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantmCRPC+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Start Los Angeles
Los Angeles, California, United States
Navid Hafez, MD, MPH
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Xin Gao, MD
Not, yet, recruiting
Start Midwest
Grand Rapids, Michigan, United States
Emerson Lim, MD
Recruiting
Start New Jersey
East Brunswick, New Jersey, United States
Bruno Fang, MD
Recruiting
Start Carolinas
Myrtle Beach, South Carolina, United States
Neal Shore, MD
Recruiting
Tennessee Oncology
Nashville, Tennessee, United States
Katy Beckermann, MD, Ph.D.
Not, yet, recruiting
Start Dallas-Fort Worth
Fort Worth, Texas, United States
Salwan Al Mutar, MD, M.Sc.
Recruiting
Next Houston
Houston, Texas, United States
Jennifer Segar, MD
Recruiting
Next Oncology
San Antonio, Texas, United States
Ildefonso Ismael Rodriguez Rivera, MD
Recruiting
Next Virginia
Fairfax, Virginia, United States
Mohamad Salkeni, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FX-111

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Jul 2026
Primary completion: 15 Feb 2028
Completion: 15 Feb 2029
Last update posted: 4 Aug 2026
Registered enrollment: 60
Registry id: NCT07719361

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.